Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.44 |
| ▸ | PYGM | P11217 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 4/20 | 0.41 |
| ▸ | ZAP70 | P43403 | 4/20 | 0.41 |
| ▸ | SYK | P43405 | 4/20 | 0.41 |
| ▸ | LYN | P07948 | 3/20 | 0.39 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1058856 | 0.85 | LRRK2 (0.52) | PARP1ZAP70SYKSMN1; SMN2ALDH1A1 | |
| SCHEMBL1058535 | 0.84 | PARP1 (0.49) | PARP1JAK2ZAP70MAPT | |
| SCHEMBL1057076 | 0.84 | JAK1 (0.41) | PARP1JAK2SYK | |
| SCHEMBL1057202 | 0.83 | SYK (0.45) | JAK2SYK | |
| SCHEMBL1056394 | 0.80 | CDK1 (0.49) | JAK2SYKSMN1; SMN2NPC1MAPT | |
| SCHEMBL1047700 | 0.80 | SYK (0.57) | JAK2ZAP70SYKSMN1; SMN2MAPT | |
| SCHEMBL15760952 | 0.79 | PARP1 (0.43) | PARP1JAK2ZAP70SYKLYN | |
| SCHEMBL24745795 | 0.79 | TYK2 (0.41) | PYGMZAP70SMN1; SMN2NPC1MAPT | |
| SCHEMBL1059533 | 0.79 | SYK (0.47) | JAK2ZAP70SYKRETFLT3 | |
| SCHEMBL30497602 | 0.77 | SYK (0.61) | PARP1JAK2ZAP70SYKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354526-B2 | Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors | IRM LLC (BM) | 2013-01-15 | — | — | US | claimed |
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | claimed |
| EP-2250169-A1 | PYRIDO [4, 3-D]PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-11-17 | — | — | EP | claimed |
| WO-2009099801-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-13 | — | — | WO | claimed |
| US-8354526-B2 | Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors | IRM LLC (BM) | 2013-01-15 | — | — | US | disclosed |
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| EP-2250169-A1 | PYRIDO [4, 3-D]PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009099801-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | ZAP70, FLT3, LCK | PARP1 1016/4885PYGM 635/4885JAK2 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.